Desmoid Tumors Market to Surpass US$ 4,375.6 Mn and expected to exhibit a CAGR of 7.3% by 2030 | Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd

Connective tissue growths known as desmoid tumours are benign. Arms, legs, and the belly are the areas where desmoid tumours typically form. The term “aggressive fibromatosis” is also used to describe desmoid tumours. Some desmoid tumours grow slowly and do not require immediate treatment. Others are treated with surgery, chemotherapy, radiation therapy, or other drugs because of their quick rate of growth.

The market for desmoid tumours is anticipated to reach US$ 2,494.1 million in 2022 and grow at a CAGR of 7.3% over the following five years (2022-2030).

Get Research Sample PDF with Market Development Insights @ https://www.coherentmarketinsights.com/insight/request-sample/5449

Drivers

Over the course of the forecast period, market growth is anticipated to be driven by a strong pipeline of new drugs for the treatment of desmoid tumours. For instance, Iterion Therapeutics announced in June 2022 that results from a Phase 1 study of tegavivint in patients with desmoid tumours would be highlighted in a poster presentation and discussion session at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022), a meeting for conducting scientific events for oncology experts, patient advocates, and other interested parties.

Over the course of the forecast period, increased technological advancements in desmoid tumour treatment are anticipated to fuel market expansion. For instance, Profound Medical, a commercial-stage medical device company, announced in June 2021 that its Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU) system had been awarded the Conformité Européenne (CE) mark for the treatment of desmoid tumours. Profound Medical develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Surgery and radiofrequency ablation are examples of conventional treatment options, both of which have special risks for patients. To enable precise, noninvasive ablation of diseased tissue, Sonalleve combines thermal ultrasound, real-time MR imaging, and thermometry. Patients with desmoid tumours now have a treatment option that can be carried out safely and improve clinical outcomes without the risks of invasive procedures, surgery, exposure to ionising radiation, or anaesthesia. Desmoid tumours are frequently difficult to treat, but MR-HIFU provides an effective treatment option. Since MR-HIFU treatment can be repeated with few side effects in the event of recurrent disease, in contrast to conventional treatment methods, it is believed that the potential benefits for patients outweigh the risks.

Impact

The disease has spread to over 100 countries since the COVID-19 virus outbreak in December 2019, and on January 30, 2020, the World Health Organization declared it to be a public health emergency.

During the COVID-19 pandemic, access to and delivery of both routine and emergency medical care have been hampered. In September 2020, data from the Centers for Disease Control and Prevention estimated that 40.9% of U.S. adults had skipped out on medical care because of COVID-19 worries, with 12% skipping urgent or emergency care and 31.5% skipping routine care. Due to COVID-19, numerous operations and various types of therapies have been delayed. Due to the number of therapies that were discontinued or postponed during the COVID-19 pandemic, the desmoid tumour market suffered. The number of radiation therapy courses in the U.K. decreased by 19% in April, 62% in May, and 16% in June of 2020 compared to the corresponding months in 2019. This is according to data published on Elsevier in January 2021. Additionally, COVID-19 has put a great deal of strain on continuing the clinical trials. Over 2,000 registered clinical trials were terminated as a result of the difficulties in conducting clinical research during the pandemic, according to the ClinicalTrials.gov report 2020.

Key developments

SpringWorks Therapeutics, a biopharmaceutical company in the clinical stages, released encouraging topline results from the phase 3 DeFi trial (NCT03785964), which examined the use of nirogacestat as a treatment for adults with progressing desmoid tumours.

Direct Purchase This Report with Huge Discount ( Up To 25% Off) @ https://www.coherentmarketinsights.com/insight/buy-now/5449

Ayala Pharmaceuticals declared in September 2022 that AL102 had received a fast track designation from the US Food and Drug Administration for the treatment of patients with developing desmoid tumours.

Restraints

The high cost of desmoid tumour treatment medications and the side effects of chemotherapy and other desmoid tumour medications are the main factors restraining the growth of the global desmoid tumour market. There is a risk of long-term side effects in many cancer survivors who have undergone chemotherapy and radiation therapy. These side effects may manifest months or years after treatment, which is anticipated to limit market expansion. For instance, chemotherapy and radiation therapy can result in serious heart, lung, endocrine system, hormonal (including infertility), brain, spinal cord, and nerve issues, as well as oral health, vision, digestion, and other issues.

Key players

Assertio Holdings, Inc., Mayne Pharma Group Limited, Alembic Pharmaceuticals Limited, Aprazer, Ayala Pharmaceuticals, SpringWorks Therapeutics, Inc., Iterion Therapeutics, Novartis AG, Apotex, and Zydus Lifesciences are major players in the global desmoid tumours market. Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Natco.

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snapshot, By Drug Type
     • Market Snapshot, By Distribution Channel
     • Market Snapshot, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Opportunity
   • Impact Analysis
   • Regulatory Scenario
   • Market Trends
   • Key Developments
   • Epidemiology
   • PEST Analysis
   • Reimbursement Scenario
   • Pipeline Analysis
   • Collaboration Scnenario
   • Treatment Option Analysis
   • Treatment Safety and Efficacy Analysis
   • Site of Activity (Mode of Action)
   • Treatment Algorithm For Desmoid Tumors
   • Disease Awareness Programs
   • Risk and Adverse effects
   • Healthcare spending by Country
   • Unmet Needs
   • Treatment Rate
4. Global Desmoid Tumors Market– Impact of Coronavirus (COVID-19) Pandemic
   • COVID-19 Epidemiology
   • Supply Side and Demand Side Analysis
   • COVID-19 Impact on the Desmoid Tumors Market
5. Global Desmoid Tumors Market, By Drug Type, 2017-2030, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Non-steroidal anti-inflammatory drugs (NSAIDs)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
   • Targeted Therapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
   • Chemotherapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
   • Hormone Therapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
   • Others
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
6. Global Desmoid Tumors Market, By Distribution Channel, 2017-2030, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
   • Online Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)